The affordability of adding a direct-acting oral anticoagulant to the national list of essential medicine for patients with non-valvular atrial fibrillation in Thailand: a budget impact analysis

References

• Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study. Circulation. 2014 Feb 25;129(8):837–847.
   PubMed Web of Science ®Google Scholar
• Morillo CA, Banerjee A, Perel P, et al. Atrial fibrillation: the current epidemic. J Geriatr Cardiol. 2017 Mar;14(3):195–203.
   PubMedGoogle Scholar
• Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006 Jul 11;114(2):119–125.
   PubMed Web of Science ®Google Scholar
• Krijthe BP, Kunst A, Benjamin EJ, et al. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur Heart J. 2013 Sep;34(35):2746–2751.
   PubMed Web of Science ®Google Scholar
• Phrommintikul A, Detnuntarat P, Prasertwitayakij N, et al. Prevalence of atrial fibrillation in Thai elderly. J Geriatr Cardiol. 2016 Mar;13(3):270–273.
   PubMedGoogle Scholar
• Odutayo A, Wong CX, Hsiao AJ, et al. Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis. BMJ. 2016 Sep;6(354):i4482.
   Google Scholar
• Kirchhof P, Ammentorp B, Darius H, et al. Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboembolic events–European Registry in Atrial Fibrillation (PREFER in AF). Europace. 2014 Jan;16(1):6–14.
   PubMed Web of Science ®Google Scholar
• Nieuwlaat R, Capucci A, Camm AJ, et al. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro heart survey on Atrial Fibrillation. Eur Heart J. 2005 Nov;26(22):2422–2434.
   PubMed Web of Science ®Google Scholar
• Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016 Oct 7;37(38):2893–2962.
   PubMed Web of Science ®Google Scholar
• January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with Atrial Fibrillation: a report of the American college of cardiology/American heart association task force on clinical practice guidelines and the heart rhythm society in collaboration with the society of thoracic surgeons. Circulation. 2019 Jul 9;140(2):e125–e151.
   PubMed Web of Science ®Google Scholar
• Perreault S, de Denus S, White-Guay B, et al. Oral anticoagulant prescription trends, profile use, and determinants of adherence in patients with Atrial Fibrillation. Pharmacotherapy. 2020 Jan;40(1):40–54. .
   PubMed Web of Science ®Google Scholar
• Wong SL, Marshall LZ, Lawson KA. Direct oral anticoagulant prescription trends, switching patterns, and adherence in Texas Medicaid. Am J Manag Care. 2018 Jul;24(8Spec No.): SP309-SP314.
   Google Scholar
• Sithitsook S Thai guideline for diagnosis and treatment of atrial fibrillation 2012 [cited 2018 Febuary 6]: http://www.thaiheart.org/images/column_1291454908/Thai_AF_Guideline_2012.pdf
   Google Scholar
• Saokaew S, Sapoo U, Nathisuwan S, et al. Anticoagulation control of pharmacist-managed collaborative care versus usual care in Thailand. Int J Clin Pharm. 2012 Feb;34(1):105–112.
   PubMed Web of Science ®Google Scholar
• Methavigul K, Boonyapisit W. Optimal INR level in Thai atrial fibrillation patients who were receiving warfarin for stroke prevention in Thailand. J Med Assoc Thai. 2014 Dec;97(12):1274–1280.
   PubMedGoogle Scholar
• Sterne JA, Bodalia PN, Bryden PA, et al. Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis. Health Technol Assess. 2017 Mar;21(9):1–386.
   Web of Science ®Google Scholar
• Lip GY, Mitchell SA, Liu X, et al. Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups. Int J Cardiol. 2016 Feb;1(204):88–94.
   Google Scholar
• Dilokthornsakul P, Nathisuwan S, Krittayaphong R, et al. Cost-effectiveness analysis of non-vitamin K antagonist oral anticoagulants versus warfarin in Thai patients with non-valvular Atrial Fibrillation. Heart Lung Circ. 2020 Mar;29(3):390–400.
   PubMed Web of Science ®Google Scholar
• Jarungsuccess S, Taerakun S. Cost-utility analysis of oral anticoagulants for nonvalvular atrial fibrillation patients at the police general hospital, Bangkok, Thailand. Clin Ther. 2014 Oct 1;36(10):1389–94 e4.
   PubMed Web of Science ®Google Scholar
• Rattanachotphanit T, Limwattananon C, Waleekhachonloet O, et al. Cost-effectiveness analysis of direct-acting oral anticoagulants for stroke prevention in Thai patients with non-valvular Atrial Fibrillation and a high risk of bleeding. Pharmacoeconomics. 2019 Feb;37(2):279–289.
   PubMed Web of Science ®Google Scholar
• Sullivan SD, Mauskopf JA, Augustovski F, et al. Budget impact analysis-principles of good practice: report of the ISPOR 2012 budget impact analysis good practice ii task force. Value Health. 2014 Jan-Feb;17(1):5–14.
   PubMed Web of Science ®Google Scholar
• Division SaP. Public health statistics A.D.2018. Nonthaburi, Thailand: Ministry of Public Health; 2019.
   Google Scholar
• Krittayaphong R, Winijkul A, Methavigul K, et al. Risk profiles and pattern of antithrombotic use in patients with non-valvular atrial fibrillation in Thailand: a multicenter study. BMC Cardiovasc Disord. 2018 Aug 25;18(1):174.
   PubMedGoogle Scholar
• National Drug System Development Committee. Median drug price announcement. Bangkok: Royal Gazette in Thailand; 2017.
   Google Scholar
• Canestaro WJ, Patrick AR, Avorn J, et al. Cost-effectiveness of oral anticoagulants for treatment of atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2013 Nov;6(6):724–731.
   PubMed Web of Science ®Google Scholar
• Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011 May 31;123(21):2363–2372.
   PubMed Web of Science ®Google Scholar
• Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011 Sep 15;365(11):981–992.
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011 Sep 8;365(10):883–891.
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013 Nov 28;369(22):2093–2104.
   PubMed Web of Science ®Google Scholar
• Kongbunkiat K, Kasemsap N, Thepsuthammarat K, et al. National data on stroke outcomes in Thailand. J Clin Neurosci. 2015 Mar;22(3):493–497.
   PubMed Web of Science ®Google Scholar
• Srimahachota S, Boonyaratavej S, Kanjanavanit R, et al. Thai Registry in Acute Coronary Syndrome (TRACS)–an extension of Thai Acute Coronary Syndrome registry (TACS) group: lower in-hospital but still high mortality at one-year. J Med Assoc Thai. 2012 Apr;95(4):508–518.
   PubMedGoogle Scholar
• Sangchan A, Sawadpanitch K, Mairiang P, et al. Hospitalized incidence and outcomes of upper gastrointestinal bleeding in Thailand. J Med Assoc Thai. 2012 Jul;95(Suppl 7):S190–5.
   PubMedGoogle Scholar
• Strategy and Planning Division Ministry of Public Health. Public health statistics A.D. 2014. Ministry of Public Health; 2015.
   Google Scholar
• Bank of Thailand. Rate of exchange of commercial banks Bangkok 2020 [cited 2020 Jul 8]. Available from: https://www.bot.or.th/english/
   Google Scholar
• Division of Trade Information and Econoimc Indices Ministry of Commerce. Consumer price index 2020 [cited 2020 Jul 8]. Available from: http://www.price.moc.go.th/
   Google Scholar
• Leelahavarong P. Budget impact analysis. J Med Assoc Thai. 2014 May;97(Suppl 5):S65–71.
   PubMedGoogle Scholar
• Dilokthornsakul P, Chaiyakunapruk N, Nimpitakpong P, et al. Understanding medication oversupply and its predictors in the outpatient departments in Thailand. BMC Health Serv Res. 2014 Sep;19(14):408.
   Google Scholar
• Calabro P, Gragnano F, Cesaro A, et al. Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and atrial thrombosis: an appraisal of current evidence. Arch Cardiovasc Dis. 2020 Oct;113(10):642–651.
   PubMed Web of Science ®Google Scholar
• Corpataux N, Spirito A, Gragnano F, et al. Validation of high bleeding risk criteria and definition as proposed by the academic research consortium for high bleeding risk. Eur Heart J. 2020 Oct 7;41(38):3743–3749.
   PubMed Web of Science ®Google Scholar
• Ueki Y, Bar S, Losdat S, et al. Validation of the Academic Research Consortium for High Bleeding Risk (ARC-HBR) criteria in patients undergoing percutaneous coronary intervention and comparison with contemporary bleeding risk scores. EuroIntervention. 2020 Aug 28;16(5):371–379.
   PubMed Web of Science ®Google Scholar
• Gragnano F, Calabro P, Valgimigli M. Is triple antithrombotic therapy, or rather its duration and composition, the true culprit for the excess of bleeding events observed in patients with atrial fibrillation undergoing coronary intervention? Eur Heart J. 2019 Jan 7;40(2):216–217.
   PubMed Web of Science ®Google Scholar